Long Yu | Biosensor | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Long Yu | Biosensor | Best Researcher Award

Assoc. Prof. Dr. Long Yu | Wuhan University | China

Dr. Long Yu is a highly accomplished Han Chinese researcher, currently serving as a Postdoctoral Fellow in Clinical Medicine at Wuhan University. With a deep passion for pharmaceutical analysis, he has pioneered innovative approaches using lanthanide-based metal-organic frameworks (Ln-MOFs). His academic journey has been marked by excellence, including direct admission to a Ph.D. program and multiple national-level scholarships. Dr. Yu has published over 20 high-impact SCI papers, many in top-tier journals such as Advanced Materials, ACS Nano, and Analytical Chemistry. Recognized for his independent research capabilities, he has secured major national funding, including the NSFC Youth Project and China Postdoctoral Science Foundation grant. His work is shaping the future of biosensing and molecular diagnostics, especially in nucleic acid detection. Dr. Yu’s remarkable academic achievements, innovative research direction, and collaborative impact make him an outstanding candidate for the Best Researcher Award.

Publication Profile: 

Orcid

Education:

Dr. Long Yu’s educational background reflects a consistent trajectory of academic excellence. He completed his Bachelor of Science in Pharmacy at Shihezi University, where he graduated and was directly admitted to a Ph.D. program without an entrance exam. He pursued a Direct-Ph.D. in Pharmacy at Wuhan University, under the mentorship of Prof. Yuxiu Xiao. His doctoral research focused on the rational design and application of programmable lanthanide-based metal-organic frameworks (Ln-MOFs) in pharmaceutical analysis. Currently, he is a Postdoctoral Fellow in Clinical Medicine at Wuhan University, guided by Professors Gaosong Wu and Xiang Zhou. Through his academic journey, Dr. Yu has demonstrated strong interdisciplinary capabilities, combining pharmaceutical sciences, materials chemistry, and biosensing technology to advance the field of molecular diagnostics.

Experience:

Dr. Long Yu has cultivated deep expertise in biosensors and pharmaceutical analysis throughout his academic and research journey. He is currently a Postdoctoral Fellow in Clinical Medicine at Wuhan University, working on translational biosensing technologies with Professors Gaosong Wu and Xiang Zhou. He earned his Ph.D. in Pharmacy at Wuhan University under the supervision of Prof. Yuxiu Xiao, where he led several high-impact research projects on programmable metal-organic frameworks (MOFs). His undergraduate foundation was built at Shihezi University , where he graduated among the top of his class. Dr. Yu has served as the principal investigator for five competitive research grants, including prestigious national funding. His academic footprint includes 21 SCI-indexed publications and significant contributions to both theoretical research and practical biosensor development. He excels at multidisciplinary collaboration, combining chemistry, materials science, and clinical application—demonstrating both leadership and innovation in his research.

Awards and Honors:

Dr. Long Yu has received multiple accolades that highlight his academic and research excellence. During his Ph.D., he was awarded the National Scholarship for Graduate Students twice, a prestigious recognition of outstanding academic performance and research capabilities in China. He also received the 1st Prize for Oral Presentation at the National Academic Symposium for Pharmacy Postgraduates in , and the Excellent Poster Award at the 9th National Conference on Drug Analysis in the same year. In addition to academic awards, he has secured several competitive grants as the Principal Investigator, including the National Natural Science Foundation of China Youth Project, the China Postdoctoral Science Foundation General Program, and the Hubei Province Postdoctoral Innovation Talent Program. These achievements demonstrate both national-level recognition and institutional confidence in his independent research potential, marking him as one of the leading young scientists in his field.

Research Focus:

Dr. Long Yu’s research is centered on the rational design of programmable lanthanide-based metal-organic frameworks (Ln-MOFs) for pharmaceutical analysis and biosensing applications. His work bridges materials science and biomedical engineering, enabling high-performance detection platforms for nucleic acids, neurotransmitters, kinases, and epigenetic modifications. He has developed Ln-MOF-integrated systems with excellent selectivity, sensitivity, and biocompatibility for real-time monitoring and clinical diagnostics. A notable feature of his research is the integration of MOF materials with cutting-edge technologies such as CRISPR-Cas, nanozymes, and multivariate sensing platforms. His innovative designs contribute to amplification-free gene mutation detection, ultra-efficient nucleic acid extraction, and responsive ctDNA biosensors. Dr. Yu’s interdisciplinary approach not only expands the utility of MOFs in biomedicine but also paves the way for smart and customizable sensing systems. With 21 high-quality SCI publications and ongoing funded projects, his work is both academically significant and practically relevant in clinical diagnostics and precision medicine.

Publications Top Notes: 

  1.  Lanthanide MOF-Integrated CRISPR-Cas Technology for Amplification-Free Gene Mutation Assay

  2.  Customized Pyrophosphate Nanosensor Based on Lanthanide MOFs for Nucleic Acids Detection

  3.  Polarity Sensor Using Multivariate Lanthanide MOF for Biosensing Platforms

  4.  Levodopa Cascade Polymerization with MOF Nanozyme for Butyrylcholinesterase Dual-Mode Assay

  5.  Enhancing Kinase Detection via Programmable Lanthanide MOF with ATP-to-ADP Conversion

  6. Ultra-Efficient Nucleic Acids Extraction Using Programmable Lanthanide MOF

  7. Bioreaction-Compatible Bivariate Lanthanide MOF Sensor for ctDNA Detection

  8. Adaptable Cobalt MOF for DNA Epigenetic Modification Detection

  9. Trinity Strategy Using Perovskite Nanozyme for Biomarker Reporting

  10.  Nanoporous Crystalline Materials for Nucleic Acids Recognition

Conclusion:

In conclusion, Dr. Long Yu is highly suitable for the Best Researcher Award based on his exceptional research productivity, innovation in the design and application of Ln-MOFs, and substantial contributions to high-impact journals. His early career achievements, particularly as a postdoctoral fellow, show a promising trajectory that is well-aligned with the criteria of research excellence, originality, and potential societal impact. With continued international exposure, broader interdisciplinary collaboration, and efforts to translate research into clinical or industrial outcomes, Dr. Yu is not only deserving of the current award but is also poised to become a leading figure in his field in the years to come.

Naoki Harada | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Naoki Harada | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Naoki Harada, Osaka Metropolitan University, Japan

Naoki Harada is an Associate Professor at Osaka Metropolitan University, Japan, with extensive expertise in molecular biology, biochemistry, endocrinology, and nutrition. He earned his Ph.D. in Life Sciences from Osaka Prefecture University in 2007. Over the past two decades, Harada has made significant contributions to understanding the physiological and biochemical mechanisms underpinning metabolic diseases, particularly type 2 diabetes. His research, characterized by high citation impact (H-index of 25), centers on pancreatic β-cell function and metabolic regulation. He has published 77 peer-reviewed articles and holds a patent related to therapeutic interventions. Harada has collaborated with leading scientists like Professors Hiroshi Inui and Ryoichi Yamaji, strengthening his academic footprint in both national and international circles. A member of multiple scientific societies, Harada continues to influence the field through impactful research, industry collaboration, and educational leadership.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Consistent Research Output

    • 77 peer-reviewed publications in reputable journals (SCI, Scopus).

    • Recent high-impact studies published in Journal of Biological Chemistry, Scientific Reports, and FASEB BioAdvances.

    • Active research profile with an H-index of 25 and over 1,785 citations.

  2. Innovative Scientific Contributions

    • Identified REDD2 as a novel therapeutic target for type 2 diabetes—bridging basic research with translational medicine.

    • Works across disciplines such as molecular biology, endocrinology, and nutritional biochemistry.

  3. Project Leadership & Industry Engagement

    • Led or participated in 14 major research projects.

    • 5 consultancy/industry-based projects, reflecting application-oriented research.

  4. Academic and Collaborative Network

    • Strong academic collaborations with Professors Hiroshi Inui and Ryoichi Yamaji.

    • Member of prestigious scientific societies (e.g., Japanese Biochemical Society, Japan Society of Nutrition and Food Science).

  5. Scientific Versatility

    • Contributions span fundamental mechanisms (e.g., oxidative stress, insulin signaling) to dietary interventions (e.g., mogrol, oleamide).

    • Demonstrates ability to bridge molecular insights with systemic physiological outcomes.

⚙️ Areas for Improvement:

  1. International Visibility and Engagement

    • Expanding participation in international conferences and editorial boards could elevate his global scientific standing.

    • Pursuing cross-border collaborations would further enrich the translational value of his work.

  2. Commercialization and Patent Activity

    • While one patent is noted, increased focus on intellectual property development and biomedical commercialization could further validate his applied research strength.

  3. Outreach and Communication

    • More active public science communication (e.g., webinars, policy advocacy, media coverage) would amplify the societal impact of his research.

🎓 Education:

Naoki Harada received his Ph.D. in Life Sciences from Osaka Prefecture University, Osaka, Japan, in September 2007. His doctoral studies laid the foundation for his interdisciplinary research in molecular biology, biochemistry, and endocrinology. Harada’s academic path was driven by a keen interest in the cellular and molecular mechanisms underlying metabolic regulation, particularly in relation to glucose homeostasis and pancreatic function. His education provided him with a solid grounding in experimental techniques, critical thinking, and scientific communication, which have become hallmarks of his later work. The institution, known for excellence in biosciences, enabled Harada to cultivate a strong research acumen. His academic training was complemented by exposure to applied research, linking basic science with clinical and nutritional applications—an approach that he has continued to emphasize throughout his career. His strong educational background plays a pivotal role in his current research endeavors and professional development.

💼 Experience:

Dr. Naoki Harada began his academic career in 2008 as an Assistant Professor at the Graduate School of Life and Environmental Sciences, Osaka Prefecture University. He was promoted to Lecturer in 2015, and subsequently to Associate Professor in 2019. Since 2022, he has served as Associate Professor at the Graduate School of Agriculture, Osaka Metropolitan University. Harada has consistently combined teaching with intensive research, mentoring graduate students while advancing his lab’s focus on metabolic diseases and endocrine physiology. His experience includes leading 14 research projects, consulting on 5 industry-linked nutrition initiatives, and co-authoring over 75 scientific papers. His experience reflects a blend of academic leadership, scientific innovation, and multidisciplinary collaboration. Notably, Harada’s role in identifying REDD2 as a therapeutic target exemplifies his contribution to translational science. He maintains strong academic partnerships and actively contributes to several professional societies, making him a respected figure in Japan’s scientific community.

🔬 Research Focus:

Naoki Harada’s research is at the intersection of molecular biology, endocrinology, and nutrition science, with a particular focus on pancreatic β-cell physiology and glucose metabolism. He investigates how oxidative stress, hormonal signals, and metabolic regulators influence insulin secretion and β-cell viability. One of his pivotal contributions is identifying the REDD2 gene as a negative regulator of β-cell function, offering novel therapeutic targets for type 2 diabetes mellitus. His studies also explore nutrient-sensing pathways, G-protein-coupled receptors, and hormonal modulation of energy metabolism. Harada’s recent work delves into the effects of dietary compounds like mogrol and oleamide on metabolic health, linking molecular mechanisms to real-world dietary interventions. His ability to bridge bench science with clinical and nutritional applications sets his research apart. Through collaborations with leading experts and high-impact publications, Harada continues to advance knowledge in the prevention and treatment of metabolic disorders.

📚 Publications Top Notes:

  • 🧬 REDD2 confers pancreatic β-cell dysfunction in high-fat diet-fed mice – Journal of Biological Chemistry, 2025

  • 🦷 Androgens suppress ST3GAL1/4, modulating mucin glycosylation and microbiota in mice – Bioscience, Biotechnology, and Biochemistry, 2025

  • 🍟 CRTC1 in MC4R cells regulates dietary fat intake – FASEB BioAdvances, 2024

  • 💉 Insulin reduces ER stress-induced apoptosis in INS-1 β-cells – Physiological Reports, 2024

  • 🍬 Mogrol activates GPBAR1 and insulin secretion, alleviates hyperglycemia – Scientific Reports, 2024

  • 🔥 Androgen receptor suppresses β-adrenoceptor-mediated thermogenesis – Journal of Biological Chemistry, 2022

  • 🏥 Age-dependent sex differences in NAFLD in TSOD and db/db mice – PLOS ONE, 2022

  • 🐭 Dietary oleamide attenuates obesity in caged mice – Bioscience, Biotechnology, and Biochemistry, 2022

  • 🌿 Curcumin targets GPR55 receptor – npj Science of Food, 2022

  • 💪 Oleamide rescues muscle atrophy in small-caged mice – British Journal of Nutrition, 2021

🧾 Conclusion:

Dr. Naoki Harada demonstrates a clear trajectory of research excellence, grounded in scientific rigor and driven by impactful biomedical questions. His ability to identify molecular mechanisms (e.g., REDD2’s role in β-cell dysfunction) and propose therapeutic directions sets him apart as a leading academic in metabolic disease research. His publication record, industry collaborations, and professional memberships underscore a mature and influential academic career.

Tian Lan | Metabolic diseases | Best Researcher Award

Published on by Cell Biologist

Prof Tian Lan | Metabolic diseases | Best Researcher Award

Prof Tian Lan ,  Harbin Medical University , China

Prof. Tian Lan is a leading researcher in molecular pharmacology at Harbin Medical University, China. With over 20 completed and ongoing research projects, his work primarily addresses metabolic diseases such as fatty liver, diabetes, and cardiovascular disorders. Prof. Lan is widely recognized for his innovative approaches to drug development, which aim to improve patient outcomes through novel pharmacological targets. He has published over 60 articles in prestigious journals, contributed to multiple patents, and collaborated with esteemed institutions like UC San Diego. His dedication to advancing medical knowledge and practice has garnered him significant citations, reflecting his impactful contributions to the field. Prof. Lan’s work embodies a blend of rigorous scientific research and practical applications, positioning him as a prominent figure in the study of metabolic diseases.

Publication profile

Scopus

Strengths for the Award

Prof. Tian Lan demonstrates exceptional expertise in molecular pharmacology, particularly in the realm of metabolic diseases. His prolific output includes over 60 publications in high-impact journals, a citation index exceeding 4000, and numerous ongoing and completed research projects (20+). His innovative research has led to the identification of new pharmacological targets and the development of novel therapeutic strategies, particularly for conditions like fatty liver disease and diabetes. Notable contributions include significant findings on GSTM2 and its role in metabolic disorders, as well as advancements in understanding cordycepin’s mechanisms. His collaborative work with prestigious institutions like UC San Diego showcases his ability to foster partnerships that enhance research impact.

Areas for Improvement

While Prof. Lan has made significant strides in research, enhancing public outreach and engagement with the broader community could amplify the impact of his findings. Increased participation in conferences and workshops to disseminate knowledge more widely could also benefit both his research visibility and collaborations.

Education 

Prof. Tian Lan earned his PhD in Molecular Pharmacology from a prestigious institution, where he developed a strong foundation in pharmacological research and therapeutic strategies. His education was characterized by a rigorous curriculum that combined both theoretical knowledge and practical laboratory skills. He pursued postdoctoral studies that further enhanced his expertise in metabolic diseases, focusing on the interplay between pharmacology and cellular mechanisms. His academic journey included extensive training in advanced research methodologies, allowing him to investigate complex biological systems and their responses to pharmacological interventions. Prof. Lan’s commitment to continuous learning has led him to engage in various workshops and conferences, where he has remained abreast of the latest developments in pharmacology and related fields. This educational background has been instrumental in shaping his research focus and methodology, ultimately contributing to his success as a researcher and educator.

Experience 

Prof. Tian Lan has extensive experience in both academic and research environments, contributing significantly to the field of molecular pharmacology. He has led numerous research projects at Harbin Medical University, focusing on drug development for metabolic diseases. With over 60 publications in high-impact journals, his research has been widely cited, reflecting his influence in the scientific community. Prof. Lan has also engaged in consultancy projects, collaborating with industry partners to translate research findings into practical applications. His editorial appointments in reputable journals further underscore his expertise and leadership within the field. Additionally, he has fostered collaborations with renowned institutions like the Chinese University of Hong Kong and UC San Diego, enhancing the scope and impact of his work. His participation in professional organizations, such as AASLD and ADA, highlights his commitment to ongoing professional development and contribution to advancing research in metabolic diseases.

Research Focus

Prof. Tian Lan’s research is centered on the molecular pharmacology of metabolic diseases, particularly focusing on fatty liver disease, diabetes, gout, and cardiovascular disorders. His innovative studies aim to uncover new pharmacological targets and develop novel therapeutic strategies that address these pressing health issues. By exploring the mechanisms behind metabolic dysfunction, Prof. Lan has made significant contributions to understanding how various pathways, such as the MAPK and ASK1 signaling pathways, can be modulated to improve disease outcomes. His work with glutathione S-transferase Mu2 (GSTM2) and cordycepin has revealed potential therapeutic targets that mitigate metabolic disorders and inflammatory damage. Furthermore, his research on traditional Chinese medicine and its integration with Western pharmacology showcases his commitment to a holistic approach in treatment. Overall, Prof. Lan’s focus on molecular mechanisms and drug development positions him at the forefront of advancing therapeutic options for metabolic diseases.

Publications Top Notes

  1. Qi Nan agarwood restores podocyte autophagy in diabetic kidney disease by targeting EGFR signaling pathway 📄
  2. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies 📄
  3. Role of Gut Microecology in the Pathogenesis of Drug-Induced Liver Injury and Emerging Therapeutic Strategies 📄
  4. Fufang Zhenzhu Tiaozhi polysaccharides ameliorates high-fat diet-induced non-alcoholic steatohepatitis and intestinal flora disorders in mice 📄
  5. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action 📄
  6. Tianhuang formula ameliorates liver fibrosis by inhibiting CCL2-CCR2 axis and MAPK/NF-κB signaling pathway 📄
  7. Arbutin ameliorates liver fibrosis in mice by inhibiting macrophage recruitment and regulating the Akt/NF-κB and Smad signaling pathways 📄
  8. FTZ polysaccharides ameliorate kidney injury in diabetic mice by regulating gut-kidney axis 📄
  9. Glaucocalyxin A attenuates carbon tetrachloride-induced liver fibrosis and improves the associated gut microbiota imbalance 📄

Conclusion

Prof. Tian Lan’s robust research portfolio, significant contributions to pharmacology, and commitment to advancing our understanding of metabolic diseases position him as a leading candidate for the Best Researcher Award. His work not only contributes to academic knowledge but also holds the potential for substantial clinical applications, ultimately improving patient outcomes in metabolic health. Recognizing his achievements with this award would validate his impact on the field and inspire further innovation in research.